GLP-1 Collective

Policy Tracker · Patient Lens · August 8, 2026

Five patients now say Novo Nordisk's own pricing caused their bills

Each lawsuit picks a different culprit, from list prices to marketing claims, and the answers could reshape what you pay next.

Nothing new was filed in the last day. These are the 7 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Novo Nordisk faces lawsuit over GLP-1 practices](/lawsuits/cl-73689631)**.

**[Lawsuit claims Novo Nordisk misled patients on GLP-1 access](/lawsuits/cl-73688845)**.

**[Parker v. Novo Nordisk: What's at stake](/lawsuits/cl-73687557)**.

**[Buslepp sues Novo Nordisk over GLP-1 pricing and marketing](/lawsuits/cl-73687305)**.

**[Otey sues Novo Nordisk over Ozempic and Wegovy pricing](/lawsuits/cl-73682968)**.

**[Schoonover sues Eli Lilly over GLP-1 drugs](/lawsuits/cl-73681962)**.

**[Novo Nordisk faces lawsuit over GLP-1 pricing and marketing](/lawsuits/cl-73679065)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.